Efficacy of concurrent chemoradiotherapy combined with nimotuzumab in the treatment of nasopharyngeal carcinoma with cervical lymph node metastasis

被引:2
|
作者
Lu, Jinlong [1 ]
Wei, Jiazhang [1 ,2 ]
Xiao, Xin [3 ,4 ]
Wei, Yunzhong [1 ]
Li, Min [1 ]
Huang, Yongta [5 ]
Deng, Weiming [1 ]
Wang, Hanwei [1 ]
Gui, Zhi [1 ]
Liu, Fei [6 ]
Jiang, He [1 ]
Zhang, Jintao [1 ]
Weng, Jingjin [1 ]
Qu, Shenhong [1 ,2 ]
机构
[1] Peoples Hosp Guangxi Zhuang Autonomous Reg, Dept Otolaryngol & Head & Neck, Nanning 530021, Peoples R China
[2] Guangxi Acad Med Sci, Inst Oncol, Nanning 530021, Peoples R China
[3] Peoples Hosp Guangxi Zhuang Autonomous Reg, Ctr Optometry & Visual Sci, Nanning 530021, Peoples R China
[4] Peoples Hosp Guangxi Zhuang Autonomous Reg, Dept Sci Res, Nanning 530021, Peoples R China
[5] Peoples Hosp Guangxi Zhuang Autonomous Reg, Dept Pathol, Nanning 530021, Peoples R China
[6] Peoples Hosp Guangxi Zhuang Autonomous Reg, Res Ctr Med Sci, Nanning 530021, Peoples R China
基金
中国国家自然科学基金;
关键词
Nasopharyngeal carcinoma; Prognosis; Chemoradiotherapy; Nimotuzumab; GROWTH-FACTOR RECEPTOR; KI-67; EXPRESSION; CANCER; RADIOTHERAPY; KI67; HEAD;
D O I
10.1007/s00405-022-07805-w
中图分类号
R76 [耳鼻咽喉科学];
学科分类号
100213 ;
摘要
Objectives First, we retrospectively compared the clinical efficacy of concurrent chemoradiotherapy combined with nimotuzumab vs. chemoradiotherapy alone in patients with nasopharyngeal carcinoma (NPC) and cervical lymph node metastasis. Second, we analyzed the value of Ki-67 as a predictor of nimotuzumab efficacy. Methods From January 2012 to December 2019, 1250 patients with cervical lymph node metastasis eligible for enrollment were included, of whom 383 were treated with concurrent chemoradiotherapy combined with nimotuzumab (targeted therapy group), and 867 were treated with concurrent chemoradiotherapy (CRT group). A total of 381 pairs of patients were matched using 1:1 propensity score matching, and differences in clinical prognosis were compared between the two groups. Results Overall survival (OS) (P = 0.028), disease-free survival (DFS) (P = 0.040), and distant metastasis-free survival (DMFS) (P = 0.040) were better in the targeted therapy compared to the CRT group. Multivariate analysis revealed that clinical staging, chemotherapy, and nimotuzumab therapy were predictors of OS and DFS. In the targeted therapy group, patients with >= 50% Ki-67 positivity had better OS and DFS rates than those with < 50% Ki-67 positivity. Conclusions In patients with stage N1-3 NPC and lymph node metastasis, the addition of nimotuzumab to concurrent chemoradiotherapy may provide additional survival benefits. Ki-67 is a potential biomarker with clinical predictive value for the efficacy of nimotuzumab combined with chemoradiotherapy.
引用
收藏
页码:2479 / 2488
页数:10
相关论文
共 50 条
  • [1] Efficacy of concurrent chemoradiotherapy combined with nimotuzumab in the treatment of nasopharyngeal carcinoma with cervical lymph node metastasis
    Jinlong Lu
    Jiazhang Wei
    Xin Xiao
    Yunzhong Wei
    Min Li
    Yongta Huang
    Weiming Deng
    Hanwei Wang
    Zhi Gui
    Fei Liu
    He Jiang
    Jintao Zhang
    Jingjin Weng
    Shenhong Qu
    [J]. European Archives of Oto-Rhino-Laryngology, 2023, 280 : 2479 - 2488
  • [2] Efficacy and survival analysis of nimotuzumab combined with concurrent chemoradiotherapy in the treatment of locally advanced nasopharyngeal carcinoma
    Wang, Lili
    Zhuang, Hengzhao
    Xu, Xiaoyan
    Zhou, Juying
    Jiao, Yang
    [J]. FRONTIERS IN ONCOLOGY, 2023, 13
  • [3] Nimotuzumab combined with concurrent chemoradiotherapy benefits patients with advanced nasopharyngeal carcinoma
    Li, Zhanzhan
    Li, Yanyan
    Yan, Shipeng
    Fu, Jun
    Zhou, Qin
    Huang, Xinqiong
    Shen, Liangfang
    [J]. ONCOTARGETS AND THERAPY, 2017, 10 : 5445 - 5458
  • [4] Long-term Efficacy of Microwave Hyperthermia Combined with Chemoradiotherapy in Treatment of Nasopharyngeal Carcinoma with Cervical Lymph Node Metastases
    Kang, Min
    Liu, Wen-Qi
    Qin, Yu-Tao
    Wei, Zhu-Xin
    Wang, Ren-Sheng
    [J]. ASIAN PACIFIC JOURNAL OF CANCER PREVENTION, 2013, 14 (12) : 7395 - 7400
  • [5] A systematic analysis in efficacy and safety of nimotuzumab combined with chemoradiotherapy in treatment of advanced nasopharyngeal carcinoma
    Sun, Yunqin
    Wang, Yaofeng
    Guan, Liping
    [J]. EUROPEAN ARCHIVES OF OTO-RHINO-LARYNGOLOGY, 2023, 280 (03) : 1183 - 1190
  • [6] A systematic analysis in efficacy and safety of nimotuzumab combined with chemoradiotherapy in treatment of advanced nasopharyngeal carcinoma
    Yunqin Sun
    Yaofeng Wang
    Liping Guan
    [J]. European Archives of Oto-Rhino-Laryngology, 2023, 280 : 1183 - 1190
  • [7] Nimotuzumab combined with concurrent chemoradiotherapy in locally advanced nasopharyngeal carcinoma: a retrospective analysis
    Liu, Zhi-gang
    Zhao, Yu
    Tang, Jiao
    Zhou, Yu-juan
    Yang, Wen-juan
    Qiu, Yan-fang
    Wang, Hui
    [J]. ONCOTARGET, 2016, 7 (17) : 24429 - 24435
  • [8] Concurrent chemoradiotherapy combined with nimotuzumab in stage III–IVa nasopharyngeal carcinoma: a retrospective analysis
    Zhuochen Cai
    Dongni Chen
    Wenze Qiu
    Chixiong Liang
    Yingying Huang
    Jiayu Zhou
    Zejiang Zhan
    Yanqun Xiang
    Xiang Guo
    Xing Lv
    [J]. Journal of Cancer Research and Clinical Oncology, 2023, 149 : 2327 - 2344
  • [9] Research on the efficacy of cisplatin and nimotuzumab combined with concurrent chemoradiotherapy on locally advanced cervical cancer
    Cao, Ye
    Deng, Li
    Lian, Shixian
    Jiang, Ying
    [J]. JOURNAL OF BUON, 2019, 24 (05): : 2013 - 2019
  • [10] Concurrent chemoradiotherapy combined with nimotuzumab in stage III-IVa nasopharyngeal carcinoma: a retrospective analysis
    Cai, Zhuochen
    Chen, Dongni
    Qiu, Wenze
    Liang, Chixiong
    Huang, Yingying
    Zhou, Jiayu
    Zhan, Zejiang
    Xiang, Yanqun
    Guo, Xiang
    Lv, Xing
    [J]. JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY, 2023, 149 (06) : 2327 - 2344